Amarin (AMRN) Competitors $10.91 -0.07 (-0.64%) Closing price 04:00 PM EasternExtended Trading$10.90 -0.01 (-0.09%) As of 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AMRN vs. AVDL, VIR, AVXL, BCAX, CMRX, CDMO, DAWN, OCS, CVAC, and ABCLShould you be buying Amarin stock or one of its competitors? The main competitors of Amarin include Avadel Pharmaceuticals (AVDL), Vir Biotechnology (VIR), Anavex Life Sciences (AVXL), Bicara Therapeutics (BCAX), Chimerix (CMRX), Avid Bioservices (CDMO), Day One Biopharmaceuticals (DAWN), Oculis (OCS), CureVac (CVAC), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical products" industry. Amarin vs. Avadel Pharmaceuticals Vir Biotechnology Anavex Life Sciences Bicara Therapeutics Chimerix Avid Bioservices Day One Biopharmaceuticals Oculis CureVac AbCellera Biologics Amarin (NASDAQ:AMRN) and Avadel Pharmaceuticals (NASDAQ:AVDL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, community ranking, institutional ownership, media sentiment and risk. Which has more volatility & risk, AMRN or AVDL? Amarin has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Comparatively, Avadel Pharmaceuticals has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500. Which has preferable valuation and earnings, AMRN or AVDL? Amarin has higher revenue and earnings than Avadel Pharmaceuticals. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Amarin, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmarin$228.61M0.98-$59.11M-$4.00-2.73Avadel Pharmaceuticals$169.12M4.97-$160.28M-$0.52-16.71 Does the MarketBeat Community prefer AMRN or AVDL? Amarin received 494 more outperform votes than Avadel Pharmaceuticals when rated by MarketBeat users. Likewise, 73.26% of users gave Amarin an outperform vote while only 66.54% of users gave Avadel Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAmarinOutperform Votes84473.26% Underperform Votes30826.74% Avadel PharmaceuticalsOutperform Votes35066.54% Underperform Votes17633.46% Does the media refer more to AMRN or AVDL? In the previous week, Amarin had 12 more articles in the media than Avadel Pharmaceuticals. MarketBeat recorded 16 mentions for Amarin and 4 mentions for Avadel Pharmaceuticals. Avadel Pharmaceuticals' average media sentiment score of 1.36 beat Amarin's score of 0.81 indicating that Avadel Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 3 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avadel Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate AMRN or AVDL? Amarin presently has a consensus target price of $7.00, suggesting a potential downside of 35.84%. Avadel Pharmaceuticals has a consensus target price of $19.88, suggesting a potential upside of 128.71%. Given Avadel Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Avadel Pharmaceuticals is more favorable than Amarin.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Avadel Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is AMRN or AVDL more profitable? Amarin has a net margin of -16.33% compared to Avadel Pharmaceuticals' net margin of -52.53%. Amarin's return on equity of -7.22% beat Avadel Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Amarin-16.33% -7.22% -4.96% Avadel Pharmaceuticals -52.53%-93.34%-44.77% Do insiders and institutionals have more ownership in AMRN or AVDL? 22.3% of Amarin shares are owned by institutional investors. Comparatively, 69.2% of Avadel Pharmaceuticals shares are owned by institutional investors. 2.0% of Amarin shares are owned by company insiders. Comparatively, 4.8% of Avadel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryAvadel Pharmaceuticals beats Amarin on 10 of the 18 factors compared between the two stocks. Get Amarin News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMRN vs. The Competition Export to ExcelMetricAmarinPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$224.03M$6.84B$5.55B$8.04BDividend YieldN/A2.95%5.09%4.22%P/E Ratio-121.227.4422.6818.83Price / Sales0.98257.63404.28106.72Price / CashN/A65.8538.1834.62Price / Book8.086.576.794.33Net Income-$59.11M$143.14M$3.22B$247.97M7 Day Performance4.60%3.59%2.44%2.71%1 Month Performance26.27%6.00%3.78%3.37%1 Year Performance-40.58%-2.03%17.05%5.80% Amarin Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMRNAmarin0.5536 of 5 stars$10.91-0.6%$7.00-35.8%-34.6%$224.03M$228.61M-121.22360Upcoming EarningsAVDLAvadel Pharmaceuticals2.4203 of 5 stars$8.75-0.2%$19.88+127.1%-53.0%$845.50M$169.12M-11.0870Upcoming EarningsPositive NewsVIRVir Biotechnology2.5125 of 5 stars$6.10-0.3%$33.57+450.4%-30.4%$842.19M$63.71M-1.56580AVXLAnavex Life Sciences3.8384 of 5 stars$9.58+1.7%$44.00+359.3%+152.3%$814.91MN/A-17.4240Upcoming EarningsNews CoveragePositive NewsBCAXBicara TherapeuticsN/A$14.81+1.9%$32.43+119.0%N/A$807.49MN/A0.0032Analyst RevisionNews CoveragePositive NewsGap DownCMRXChimerix3.0157 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212,000.00-9.0990Analyst ForecastCDMOAvid Bioservices0.7327 of 5 stars$12.50+0.1%$12.25-2.0%+62.9%$799.18M$139.91M-5.23320High Trading VolumeDAWNDay One Biopharmaceuticals2.5601 of 5 stars$7.74flat$32.29+317.1%-56.9%$784.48M$131.16M-7.5160Upcoming EarningsNews CoverageOCSOculis2.7534 of 5 stars$17.86+5.1%$30.25+69.4%+38.0%$779.80M$980,000.00-9.252Positive NewsCVACCureVac3.8685 of 5 stars$3.47+7.4%$16.00+361.1%+28.3%$778.45M$535.18M6.31880Analyst ForecastGap UpABCLAbCellera Biologics2.4018 of 5 stars$2.59+0.8%$7.50+189.6%-34.1%$771.79M$28.83M-4.25500Upcoming Earnings Related Companies and Tools Related Companies Avadel Pharmaceuticals Alternatives Vir Biotechnology Alternatives Anavex Life Sciences Alternatives Bicara Therapeutics Alternatives Chimerix Alternatives Avid Bioservices Alternatives Day One Biopharmaceuticals Alternatives Oculis Alternatives CureVac Alternatives AbCellera Biologics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMRN) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amarin Co. plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Amarin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AMRN Stock Free AMRN Stock Alerts